Type 2 diabetes
Conditions
Interventions
Ipragliflozin 50 mg for 12 weeks
Sponsors
Tokyo Medical and Dental University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes with BMI < 25.0 kg/m2 and HbA1c 6.5-9.0% and visceral fat area equal to or greater than 100 cm2
Exclusion criteria
Exclusion criteria: Patients who are taking SGLT2 inhibitors Patients with insulin treatment Patients with severe diabetic retinopathy Patients who are hypersensitive to SGLT2 inhibitors Patients with cogestive heart failure (NYHA classification class III or IV) Patients with active infection, malignancy, severe liver or renal diseases Patients who had recently received operation or had severe trauma Patients who had experienced atherothrombotic events including myocardila infarction and/or stroke Patients with severe ketosis or diabetic coma/pre-coma Patients who are unable to figure out the consent due to dementia or impairment of consciousness Pregnant women, lactating woman, women who are planning to get pregnant Patients who were judged inadequate to enroll in the study by medical doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of epicaridial fat volume from baseline at 12 weeks | — |
Countries
Japan
Contacts
Public ContactRyotaro Bouchi
Tokyo Medical and Dental University Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences
Outcome results
None listed